protected the kidney function to the same extent in this 6 year long study in mild and moderate primary Background. Hypertension is a significant cause of end-stage renal failure and effective treatment of hyper-hypertension. tensive will reduce the progression rate of chronic renal failure in various kidney disorders. Different classes of Key words: ACE-inhibitors; antihypertensive treatdrugs may be more effective than others in this respect. ment; betablockers; glomerular filtration rate; In this study we compared the effects on the glomerular hypertension filtration rate (GFR) of the ACE-inhibitor enalapril and the betablocker metoprolol in patients with mild and moderate primary hypertension during 6 years. Methods. Patients with GFR in the normal range (Á80 ml/min/1.73 m2 BSA) were included after a pla
(Á80 ml/min/1.73 m2 BSA) were included after a pla-Introduction cebo treatment period of 4-8 weeks if diastolic blood pressure was 100-120 mm Hg. Target blood pressure Hypertension is often claimed to be a significant cause was set to <90 mm Hg diastolic. One hundred and of end-stage renal failure [1] [2] [3] [4] . It has also been shown thirty patients were randomized in an open parallel that effective treatment of hypertension will reduce the study to receive either enalapril or metoprolol. No progression rate of chronic renal failure in glomeruloplacebo group was included. GFR was measured using nephritis, autoimmune disease and diabetes [5] [6] [7] [8] . the 51CR-EDTA clearance method and 81 patients There is surprisingly little information, however, on completed the study.
the decline of kidney function in primary hypertension Results. At inclusion, there were no significant differalthough recent evidence suggests that the progression ences regarding GFR or blood pressure between the decline is very slow indeed [9] [10] [11] . groups. The blood pressure treatment goal was reached Normally, for an individual over 50 years of age the in all patients and was maintained during the whole decrease in GFR is~1 ml/min/year in Scandinavia as observation period. A small but significant fall in GFR determined in a large group of individuals free of renal by 4 ml/min/1.73 m2 BSA was noted in both groups disease and hypertension [12] . In the case of untreated after the first year of treatment but thereafter GFR hypertensive patients there are no well controlled studdecreased by only 1 ml/min/year/1.73 m2 BSA, in both ies in recent decades with regard to decrease in GFR. groups. Body weight, serum uric acid and triglycerides However, it is a well-known fact that impaired kidney increased slightly with metoprolol treatment but no function, in some cases even uremia, was a common other differences between the two treatments were complication in primary hypertension when effective noted.
antihypertensive drugs were not available [13 ] . Conclusions. With the blood pressure maintained at It was first shown for diabetic nephropathy that the same level using either enalapril or metoprolol ACE-inhibitors may confer renal protection over and during a 6-year study period, GFR decreased to the above what is obtained by lowering the blood pressure, same extent in the two groups both during the first especially in type I [14, 15] , where the ACE-inhibitors year and thereafter. The overall magnitude of the GFR enalapril and captopril have been more beneficial than decline approached that of the normal age-related beta-blockers in protecting the kidney function. Studies decrease of kidney function, i.e. GFR decreased only have shown that this also might be valid in nonabout 1 ml/min/year. Thus, treatment with an ACEdiabetic kidney disorders [16, 17] . inhibitor, enalapril, and a beta-blocker, metoprolol, In 1986, Ljungman and co-workers [9] demonstrated that previously untreated patients with primary hyper- Table 1 . Baseline characterstics on 130 patients with primary hypertreatment using the selective beta-blocker metoprolol tension randomised to E or M. There were no significant differences as basic therapy. The mean decrease in GFR was in any parameter 2.5 ml/min/year but it was not clear if the decline was equally distributed over the observation period. At the Enalapril Metoprolol same time Bauer and co-workers [19, 20] showed that GFR in patients with primary hypertension who were enalapril and metoprolol, are also the two most used drugs for hypertension treatment in Sweden today, it is obviously of interest to discover even small, longterm differences between these two drugs. The present study was therefore designed to compare treatment with metoprolol in 11 patients and in 9 patients the effects of the ACE-inhibitor enalapril with those with enalapril in the dose of 19±9 and 13±8 mg/day, of the beta-blocker metoprolol on GFR in a study of respectively. Main reasons for leaving the study were need 3 years and, if no clearcut response was obtained, of other therapy due to uncontrolled hypertension with the continue for another 3 years, i.e. 6 years in total. study drugs in 4 patients in the metoprolol group and 2 patients in the enalapril group after 3 years and a total of 5 and 3 patients after 6 years. Other reasons for leaving the study were a wish to withdraw and adverse effects, e.g. cough was the reason for withdrawal in 6 patients in the enalapril
Patients and methods
group. There were no unexpected adverse effects. Only 3 patients were lost to follow-up. Clinical data for the two Fifteen centres of general practice and primary health care groups of patients at the start of the study are given in co-operated in this open, randomised, parallel study over 6 Table 1 . There were no differences between the groups regardyears. Both patients with previously untreated hypertension ing any of the variables. and patients with previously treated hypertension with bBlood pressure was measured using a mercury manometer selective beta-blockade (atenolol, metoprolol ) were included after 5 min rest in the supine position and after 1 min in the after a placebo treatment period of 4-8 weeks before inclu-standing position. Measurements were repeated three times sion. Inclusion criteria were a diastolic blood pressure of and the average of the last two measurements was calculated 100-120 mm Hg and a GFR in the normal range, i.e. for measurements in the supine position. For standing blood Á80 ml/min /1.73 m2 BSA. The exclusion criteria were earlier pressure only one measurement was made. Patients were stroke or myocardial infarction; angina pectoris, congestive instructed not to take the drugs before the blood pressure heart failure, claudication and primary renal disease; albu-measurements on clinical visits, which were scheduled for minuria defined as plus two or more with dip-stick, microal-8-10 am. buminuria was not measured; diabetes mellitus or fasting After randomisation, patients were seen after 1, 3, 6 and blood glucose >7 mmol/l at two separate occasions; serum 12 months during the first year and every 6 months during cholesterol >8 mmol/l; treatment with NSAIDs on chronic the following 5 years. basis; and contraindications for beta-blockade, ACE-inhibRenal function (GFR) measurements were made twice itors and/or hydrochlorothiazide. before randomisation within 2 months, every 12 months for Patients were randomised to either enalapril 20 mg the first 3 years, at the end of the study after 6 years. GFR ( Renitec, MSD) or metoprolol 100 mg (Seloken Zoc, Astra) was measured using the plasma clearance of 51CR-EDTA once daily to be taken in the morning at 8 am. Target blood [21] . The correlation between the two initial GFR measurepressure was set to <90 mm Hg diastolic blood pressure.
ments is given in Figure 1 , demonstrating the high degree of After drug titration the maximal dose was 40 mg of enalapril precision of the method. The mean of the two first GFR and 200 mg of metoprolol. If this was not sufficient to control measurements were used as the baseline value for calculation diastolic blood pressure, hydrochlorothiazide 12.5-25 mg of the rate of decline of GFR over 6 years. Haematology, o.d. was added. If this was not sufficient to control blood serum electrolytes and liver test were performed yearly using pressure the patient was withdrawn from the study. No other standard methods. drugs for hypertension treatment were allowed. The treatDifferences between groups were tested using the Student's ment period was 6 years.
t-test. Linear regression was used to calculate decline rate in The study was approved by the Ethics Committee of the GFR over time. To detect a statistical significant difference Medical Faculty, Gö teborg University, Göteborg, Sweden.
between the treatment groups of 4.5 ml/min in GFR a power A total of 130 patients were randomised into the study of 80% was chosen at the 0.05% level with a two-sided test. and after 3 and 6 years 107 and 81 remained, i.e. 82 and Taking the multicenter design into account it was calculated 62% of the patients. There was no difference in drop out rate that 130 patients should be randomised to treatment, equally between the enalapril and metoprolol groups and at the end divided between enalapril and metoprolol and that at least of the study there were 41 patients on metoprolol and 40 patients on enalapril. Hydrochlorothiazide was added to the 30 patients in each group should complete each treatment. 
Results

Blood pressure management
Initial systolic and diastolic blood pressures were the same in the two groups and the treatment blood pressure goal was reached in all patients. Mean systolic and diastolic blood pressures during the study are shown in Figure 2a . The mean arterial blood pressure ( Figure 2b ) was slightly and significantly more reduced in the enalapril group than in the metoprolol group after 12 and 24 months, but not after 30 months and thereafter. The mean systolic and diastolic blood pressure in the two groups during the study were 143±13/87±5 mm Hg for enalapril and 147±12/89±6 mm Hg for metoprolol ( NS). At the end of the study 31 patients had only enalapril Fig. 2a . Supine systolic and diastolic blood pressure in the enalapril and metoprolol groups. and 30 patients had only metoprolol while 9 patients Symbols: # enalapril, $ metoprolol. *difference at P<0.05.
had enalapril and 10 patients metoprolol in combina- 
Glomerular filtration rate
shown in Figure 4 . GFR decreased during the first There was no difference in GFR between the two year by −3.1 and −4.1 ml/min and thereafter by −0.6 groups when comparing means of the two initial measand −1.0 ml/min/year for enalapril and metoprolol, urements before randomization at the start of the study respectively (NS ). being 95±16 ml/min for the enalapril group and 93±14 ml/min for the metoprolol group (NS).
Additional observations Calculating the rate of decline in GFR in the two groups shows there was no difference as shown in During the first 3 years, serum uric acid, triglycerides Figure 3 . The rate of change of GFR for the whole and body weight increased significantly during metopperiod was −1.4±2.6 and −1.1±2.4 ml/min/year for rolol treatment as shown in Figure 5 . These differences enalapril and metoprolol, respectively ( NS). Half of then disappeared. the decrease in GFR took place during the first year and the rest during the following 5 years and to the Discussion same extent in the two groups. During the last 5 years the mean decline in GFR was <1 ml/min/year.
Calculating the rate of decline for those patients With the sophistication of today's antihypertensive treatment it would be interesting to note any differences that completed all 6 years yielded similar results as There were minor increases with metoprolol but no changes with enalapril treatment. *difference at P<0.05 during the first years but thereafter there were no differences. Fig. 4 . GFR (mean±SE) in 81 patients treated for hypertension for 6 years with enalapril (mean dosage 25±11 mg/day) and metoprolol groups of patients within these narrow limits would (mean dosage 126±57 mg/day). Shaded area denotes the normal require really long term studies and methods with good range of age adjusted GFR. There were no significant differences between the groups. precision.
We have now concluded a 6-year study aiming at detecting differences in kidney function between the drugs enalapril and metoprolol in mild and moderate between treatment regimes even if they are small. With the success of ACE-inhibitors came the idea that primary hypertension. However, we could find no difference in GFR between the two groups of patients kidney function might be preserved better with these drugs than with the previous antihypertensive drugs, over this long period of time. The patients were successfully maintained on the same blood pressure level. i.e. ACE-inhibitors may confer renal protection. In fact, this was shown in diabetes mellitus [14, 15] and Therefore, in primary hypertension it seems as if the blood pressure reduction is the important parameter subsequently also in other kidney disorders [16, 17] .
In mild and moderate primary hypertension repres-in preserving kidney function and not the particular drug. entative data are sparse. The most convincing data of progression of kidney function has been given by
We have also observed that the deterioration in kidney function is slower than anticipated from the Ljungman et al. [9, 18, 26 ] showing that groups of hypertensive patients defined on an epidemiological early studies of Ljungman et al. [9, 18] . We would have expected GFR to be reduced by 15 ml/min during the basis progressed rather slowly when given effective antihypertensive treatment. Nevertheless, the progres-study period of 6 years, but in fact it was only decreased by 7-8 ml/min, i.e. half the anticipated rate of decline. sion rate for the glomerular filtration rate was more than double that of normal ageing, i.e. 2.5 vs. In fact, the rate of GFR decline by 1 ml/min/year in this study with target blood pressure below 90 mm Hg 1 ml/min/year. Obviously, to detect differences between
